Drug major Glenmark Pharmaceuticals has become the first Indian company to commercially launch an antiviral drug for the treatment of mild to moderate COVID-19 patients after it received the Indian drug regulator Drug Controller General of India (DCGI) approval.
The drug Favipiravir, under the brand name FabiFlu, will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said. Effectively, one tablet of FabiFlu would cost Rupees 103.
It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, the drug firm said.
- Glenmark is the first pharma firm to get approval for an oral drug to treat COVID-19 patients in India.
- Priced at Rs 3,500 for 34 tablets, the dosage is 200 mg X 9 tablets on day one and 200 mg X 4 tablets a day for 14 days.
- Global trials show the efficacy of over 80-88%; Japan, Bangladesh and UAE already use the drug for COVID-19 treatment.
- The drug will be available both through hospitals and the retail channel.
- Reportedly, Strides Pharma, Brinton Pharmaceuticals, Lasa Supergenerics and Optimus Pharma among firms readying its launch
- Glenmark had developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu through in-house R&D.
- Favipiravir is backed by strong clinical evidence, showing encouraging results in patients with mild to moderate Covid-19.
- Patients from over 10 leading government and private hospitals were enrolled for the study.
- It offers rapid reduction in viral load within four days and provides faster symptomatic and radiological improvement.
- Favipiravir has shown clinical improvement of up to 88 per cent in mild to moderate COVID-19 cases.
- Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections.